Investment in health care, R&D robust in China and Hong Kong despite COVID-19

As health care firms in China and Hong Kong race to respond to the challenges of the global COVID-19 pandemic, they are experiencing sustained investment (mostly from China funds and wealthy Chinese investors), and are benefiting from recent regulatory changes and technological advances.

Among the shifts are the emergence of artificial intelligence and data privacy technologies, as consumers increasingly seek to book appointments and receive diagnosis and treatment online. Those shifts are aided by government efforts to streamline regulations, speed approval of new drug treatments and medical devices, and promote innovation. In addition, the Chinese government is strengthening protections on intellectual property.